Equities research analysts at Morgan Stanley started coverage on shares of Pharmacyclics (NASDAQ: PCYC) in a research note issued to investors on Tuesday. The firm set an “equal weight” rating on the stock.
PCYC has been the subject of a number of other recent research reports. Analysts at RBC Capital raised their price target on shares of Pharmacyclics from $60.00 to $70.00 in a research note to investors on Tuesday, February 19th. Separately, analysts at JMP Securities raised their price target on shares of Pharmacyclics from $104.00 to $107.00 in a research note to investors on Tuesday, February 19th. Finally, analysts at Leerink Swann downgraded shares of Pharmacyclics from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday, February 19th. They now have a $97.00 price target on the stock, up previously from $80.00.
Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Pharmacyclics presently has a consensus rating of “Buy” and a consensus price target of $93.20.
Shares of Pharmacyclics (NASDAQ: PCYC) traded up 2.26% during mid-day trading on Tuesday, hitting $88.58. Pharmacyclics has a one year low of $24.50 and a one year high of $95.85. The stock’s 50-day moving average is currently $82.90. The company has a market cap of $6.248 billion and a P/E ratio of 73.28.
Pharmacyclics (NASDAQ: PCYC) last released its earnings data on Thursday, February 14th. The company reported $0.62 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.29 by $0.33. The company had revenue of $57.96 million for the quarter, compared to the consensus estimate of $45.74 million. During the same quarter in the prior year, the company posted $0.82 earnings per share. The company’s quarterly revenue was down 25.6% on a year-over-year basis. Analysts expect that Pharmacyclics will post $-0.26 EPS for the current fiscal year.
Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.